Theravance Biopharma, Inc. (TBPH)

A forensic read on Theravance Biopharma, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

Theravance Biopharma is a biopharmaceutical company primarily focused on the development and commercialization of medicines, with its main approved product being yupelri (revefenacin) for chronic obstructive pulmonary disease (COPD). Revenue grew significantly from $64.4 million in FY2024 to $107.5 million in FY2025, an increase of 66.9%, while net margin expanded from -87.6% in FY2024 to 98.5% in FY2025.

← Browse all forensic stock analyses

Data from SEC EDGAR public filings. Forensic signals flag probability, not certainty.